Notably, no cases of clinically significant hypoglycemia, medullary thyroid cancer, or C-cell hyperplasia were reported in published trial data
Key Differences Summary# Conclusion# Liraglutide represents a meaningful advancement over exenatide across glycemic control (LEAD-6 and DURATION-6 head-to-head superiority), weight management (only agent with FDA obesity approval among the two), cardiovascular outcomes (LEADER superiority vs EXSCEL non-inferiority), and tolerability (less persistent nausea, no injection site nodules, minimal immunogenicity)
Moreover, GHK has been shown to be a quencher for hydroxyl and peroxyl radicals by ESR spectroscopy, with its ability to quench hydroxyl radicals much stronger than glutathione (GSH), making it a strong endogenous antioxidant [20]
51 Ben-JonathanNHugoERBrandebourgTDLaPenseeCR
This article is part of the special issue on Glucose Transporters in Health and Disease in Pflgers ArchivEuropean Journal of Physiology Rights and permissions About this article Cite this article Bertrand, L., Auquier, J., Renguet, E
